These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11866282)

  • 21. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S; Orito E; Mizokami M
    J Med Virol; 1996 Apr; 48(4):354-9. PubMed ID: 8699168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C.
    Hayashi J; Ohmiya M; Kishihara Y; Tani Y; Kinukawa N; Ikematsu H; Kashiwagi S
    Am J Gastroenterol; 1994 Dec; 89(12):2151-6. PubMed ID: 7977232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients.
    Missale G; Cariani E; Lamonaca V; Ravaggi A; Rossini A; Bertoni R; Houghton M; Matsuura Y; Miyamura T; Fiaccadori F; Ferrari C
    Hepatology; 1997 Sep; 26(3):792-7. PubMed ID: 9303515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histological changes but not virus eradication reflect biochemical improvement in chronic hepatitis C patients showing a long-term response to interferon alpha therapy.
    Bruno S; Manzin A; Roncalli M; Petroni ML; Rossi S; Pedicino M; Larghi A; Crosignani A; Podda M
    Ital J Gastroenterol Hepatol; 1997 Feb; 29(1):31-7. PubMed ID: 9265576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C.
    Chayama K; Tsubota A; Kobayashi M; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1996 May; 23(5):953-7. PubMed ID: 8621174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin.
    Legrand-Abravanel F; Sandres-Sauné K; Barange K; Alric L; Moreau J; Desmorat P; Vinel JP; Izopet J
    J Infect Dis; 2004 Apr; 189(8):1397-400. PubMed ID: 15073676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
    J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience.
    Srinivas D; Mani H; Crumpler C; Van Thiel DH
    Hepatogastroenterology; 2002; 49(46):1053-7. PubMed ID: 12143200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation.
    Di Martino V; Saurini F; Samuel D; Gigou M; Dussaix E; Reynès M; Bismuth H; Féray C
    Hepatology; 1997 Nov; 26(5):1343-50. PubMed ID: 9362382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy.
    Shindo M; Hamada K; Koya S; Arai K; Sokawa Y; Okuno T
    Hepatology; 1996 Nov; 24(5):1018-23. PubMed ID: 8903369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.
    Arase Y; Suzuki F; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Kobayashi M; Sezaki H; Ikeda K; Kumada H
    Intervirology; 2004; 47(1):19-25. PubMed ID: 15044832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative evaluation of serum HCV RNA by Roche Monitor Assay. Versions 1.0 and 2.0; as a predictive marker of subsequent response to IFN therapy].
    Takenokuchi M; Yasuda C; Nakamachi Y; Mukai M; Yoon S; Kondoh S; Kumagai S
    Rinsho Byori; 2002 Apr; 50(4):392-7. PubMed ID: 12014019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection.
    Tsubota A; Chayama K; Ikeda K; Yasuji A; Koida I; Saitoh S; Hashimoto M; Iwasaki S; Kobayashi M; Hiromitsu K
    Hepatology; 1994 May; 19(5):1088-94. PubMed ID: 8175130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S
    Am J Gastroenterol; 1996 Apr; 91(4):743-7. PubMed ID: 8677941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus.
    Lee JH; Teuber G; von Wagner M; Roth WK; Zeuzem S
    J Med Virol; 2000 Mar; 60(3):264-8. PubMed ID: 10630957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.